

05-09-05

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

12

Application Number	10/664,513
Filing Date	September 16, 2003
First Named Inventor	Marc K. HELLERSTEIN
Art Unit	1645
Examiner Name	Not Yet Assigned

Attorney Docket Number

416272003700

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. PTO/SB/08a/b (8 pages) 2. 97 Cited References 3. Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement, (Supplemental, 3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer No. 20872)		
Signature			
Printed name	Michael R. Ward		
Date	May 5, 2005	Reg. No.	38,651

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV731514203US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated: May 5, 2005

Signature:

(Laura Tsang)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 731514203 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 5, 2005

Signature: 

(Laura Tsang)

Patent

Docket No. 416272003700

B01-074

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Marc K. HELLERSTEIN

Serial No.: 10/664,513

Filing Date: September 16, 2003

For: BIOCHEMICAL METHODS FOR
MEASURING METABOLIC FITNESS
OF TISSUES OR WHOLE ORGANISMS

Examiner: Not Yet Assigned

Group Art Unit: 1645

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.

A fee is required. A check in the amount of __ is enclosed.

A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.

After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.

A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.

A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 416272003700.

Dated: May 5 , 2005

Respectfully submitted,

By Michael R. Ward
Michael R. Ward
Registration No.: 38,651
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
(415) 268-6237



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	8	Attorney Docket Number	416272003700
-------	---	----	---	------------------------	--------------

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
1.	US-4,332,784	06-01-1982	Smith et al.		
2.	US-5,439,803	08-08-1995	Ross et al.		
3.	US-6,653,076	11-25-2003	Franza, Jr. et al.		
4.	US-2003/0148533	08-07-2003	Malloy et al.		
5.	US-2003/0180710	09-25-2003	Lee et al.		
6.	US-2003/0180800	09-25-2003	Lee et al.		
7.	US-2003/0228259-A1	12-11-2003	Hellerstein		
8.	US-2004/0091943	05-13-2004	Schneider		
9.	US-2004/0115131-A1	06-17-2004	Hellerstein		
10.	US-2004/0152994	08-05-2004	Meier-Augenstein		
11.	US-2004/0253647	12-16-2004	Mathews et al.		
12.	US-2005/0019251-A1	01-27-2005	Hellerstein		
13.	US-2005/0053992-A1	03-10-2005	Hellerstein		
14.	US-10/519,121	FD 09-15-2003	Hellerstein		
15.	US-10/523,250	FD 01-26-2005	Hellerstein		
16.	US-10/526,860	FD 09-04-2003	Hellerstein		
17.	US-10/872,280	FD 06-17-2004	Hellerstein		
18.	US-10/963,967	FD 10-12-2004	Hellerstein		
19.	US-10/997,323	FD 11-23-2004	Hellerstein		
20.	US-11/064,197	FD 02-22-2005	Hellerstein		
21.	US-11/078,083	FD 03-11-2005	Hellerstein		
22.	US-11/094,387	FD 03-29-2005	Hellerstein		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
23.	WO-90/11371	10-04-1990	Anticancer, Inc.		
24.	WO-93/25705	12-23-1993	Barranco		
25.	WO-03/061479-A1	07/31/2003	Hellerstein		
26.	WO-03/068919-A2	08/21/2003	Hellerstein		
27.	WO-03/087314-A2	10/23/2003	Hellerstein		
28.	WO-04/003493-A2	01/08/2004	Hellerstein		
29.	WO-04/011426-A2	02/05/2004	Hellerstein		
30.	WO-04/021863-A2	03/18/2004	Hellerstein		
31.	WO-04/024941-A2	03/25/2004	Hellerstein		
32.	WO-04/025270-A2	03/25/2004	Hellerstein		

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				<i>Complete If Known</i>	
				Application Number	10/664,513
				Filing Date	September 16, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	2	of	8	Attorney Docket Number	416272003700

33.	WO-04/042360-A2	05/21/2004	Hellerstein		
34.	WO-05/009597-A2	02/03/2005	Hellerstein		
35.	WO-05/015155-A2	02/17/2005	Hellerstein		
36.	WO-05/033652-A2	04/14/2005	Hellerstein		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	37.	International Search Report mailed on January 19, 2005, for PCT application no. PCT/US03/29361 filed on September 15, 2003, 4 pages		
	38.	International Search Report mailed July 8, 2004, for PCT patent application no. PCT/US03/27623 filed on September 4, 2003, 4 pages		
	39.	International Search Report mailed on March 25, 2005, for PCT applicattion no. PCT/US04/39722 filed on November 24, 2004, 3 pages		
	40.	International Search Report mailed on August 20, 2004, for PCT application no. PCT/US03/10554 filed on April 4, 2003, 4 pages		
	41.	International Search Report mailed on July 9, 2004, for PCT application no. PCT/US03/35107 filed on November 4, 2003, 2 pages		
	42.	International Search Report mailed on June 29, 2004, for PCT application no. PCT/US03/04183 filed on February 12, 2003, 4 pages		
	43.	International Search Report mailed on April 4, 2005, for PCT application no. PCT//US04/21063 filed on June 29, 2004, 2 pages		
	44.	"New Diagnostic Technique Could Help Treat AIDS," Agence France-Presse, Dow Jones News/Retrieval, Feb. 17, 1998, pp. 1-2.		
	45.	ADAMI, H.O. et al. (1995) "The Aetiology and Pathogenesis of Human Breast Cancer" <i>Mutation Research</i> 333: 29-35		
	46.	ANDERSON, R.W. et al. (1998) "Direct HIV Cytopathicity Cannot Account for CD4 Decline in AIDS in the Presence of Homeostasis: A Worst-Case Dynamic Analysis" <i>J. AIDS and Human Retrovirology</i> 17:245-252		
	47.	ASHER, E. et al. (1995) "Evaluation of Cell Death in EBV-Transformed Lymphocytes Using Agarose Gel Electrophoresis, Light Microscopy and Electron Microscopy" <i>Leukemia and Lymphoma</i> 19:107-119		

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				Complete If Known	
				Application Number	10/664,513
				Filing Date	September 16, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	3	of	8	Attorney Docket Number	416272003700

48.	BACH, Simon P. et al. (2000) "Stem Cells: The Intestinal Stem as a Paradigm" <i>Carcinogenesis</i> 21(3): 469-476	
49.	BICKENBACH, J.R. (1981) "Identification and Behavior of Label-Retaining Cells in Oral Mucosa and Skin" <i>J Dent Res</i> 1611-1620	
50.	BLACK, G.E. et al. (January 2001) "Labeling DNA with Stable Isotopes: Economical and Practical Considerations," <i>BioTechniques</i> 30:134-140	
51.	BLAU, K. and HALKET, J. eds. (1993) <u>Handbook of Derivatives for Chromatography</u> , 2nd Edition; John Wiley & Sons Ltd., England	
52.	BRAVO, Elena et al. (1994) "Decreased Hepatic Uptake and Processing of High Density Lipoprotein Unesterified Cholesterol and Cholesteryl Ester with Age in the Rat" <i>J. Biochem.</i> 116: 1088-1095	
53.	BROWN, Alan S. et al (1998) "Treating Patients with Documented Atherosclerosis to National Cholesterol Education Program-Recommended Low-Density-Lipoprotein Cholesterol Goals with Atorvastatin, Fluvastatin, Lovastatin and Simvastatin" <i>J. Am. Coll. Cardiol.</i> 32: 665-672	
54.	BUCY, R.P. et al. (1998) "Analysis of Lymph Node Biopsies in HIV Infected Patients Before and After HAART" <i>Abstract, 5th Conference on Retroviruses and Opportunistic Infections, Session 66</i> 519:177	
55.	CALDWELL, K.A. et al. (1993) "Quantification of Peptide Isotopomer Abundances and Determination of Protein (sic) Turnover Rates by Using Mass Isotopomer Distribution Analysis" <i>Abstract, 41st Annual Amer. Society Mass Spectrometry on Mass Spectrometry</i> , p. 331a.	
56.	CASSELLA, C.R. et al. (1997) "Mechanisms of Lymphocyte Killing by HIV" <i>Current Opinion in Hematology</i> 4:24-31	
57.	CESAR, D. et al. (1998) "Direct Measurement of CD4+ and CD8+ T Cell Proliferation Rates in Vivo in AIDS Patients Using a Stable Isotope-Mass Spectrometric Technique" <i>Abstract, 5th Conference on Retroviruses and Opportunistic Infections</i> , Chicago Illinois	
58.	COHEN, A. et al. (1983) "Purine and Pyrimidine Metabolism in Human T Lymphocytes," <i>J. Biol. Chem.</i> 258(20):12334-12340	
59.	COHEN, J. (1998) "Failure Isn't What It Used to Be...But Neither is Success" <i>Science</i> 279:1133-1134	
60.	CONNERS, M. et al. (1997) "HIV Infection Induces Changes in CD4+ T-Cell Phenotype and Depletions Within the CD4+ T-Cell Repertoire that are not Immediately Restored by Antiviral or Immune-Based Therapies" <i>Nature Medicine</i> 3(5):533-540	
61.	CRAIN, P.F.(1990) "Preparation and Enzymatic Hydrolysis of DNA and	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO				Complete If Known	
				Application Number	10/664,513
				Filing Date	September 16, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	4	of	8	Attorney Docket Number 416272003700	

		RNA for Mass Spectrometry," <i>Meth. Enz.</i> 193:782-790	
62.		DEEKES, S. et al. (1998) "Viral Load and CD4+ T Cell Changes in Patients Failing Potent Protease Inhibitor Therapy" <i>Abstract, 5th Conference on Retroviruses and Opportunistic Infections</i> , Session 53, 419:158	
63.		DIMITROV, D.S. et al. (1995) Scientific Correspondence, <i>Nature</i> 375:194-195	
64.		GOROCHOV, G. et al. (1998) "Perturbation of CD4+ and CD8+ T-Cell Repertoires During Progression to AIDS and Regulation of the CD4+ Repertoire During Antiviral Therapy," <i>Nature Medicine</i> 4(2):215-221	
65.		GOZ, Barry (1978) "The Effects of Incorporation of 5-Halogenated Deoxyuridines into DNA of Eukaryotic Cells" <i>Macological Reviews</i> 29, (4): 249-272	
66.		GRATZNER, H.G. (1982) "Monoclonal Antibody to 5-Bromo-and 5-Iododeoxyuridine: A New Reagent for Detection of DNA Replication" <i>Science</i> 218:474-475	
67.		HELLERSTEIN, M.K. et al. (1997) "T Cell Turnover in HIV-1 Disease," <i>Immunity</i> 7:583-589 (Nov. 1997).	
68.		HO, D.D. et al. (1995) "Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection," <i>Nature</i> 373:123-126	
69.		HSIEH, Elaine A. et al. (2004) "Dynamics of Keratinocytes in Vivo Using ^{2}H O Labeling: A Sensitive Marker of Epidermal Proliferation State," <i>J Invest Dermatol</i> , 123: 530-536	
70.		JAMES, J.S. (1998) "Clinical Implications of Virological Failure: Interview with Steven Deeks, M.D., San Francisco General Hospital," <i>AIDS Treatment News</i> , 289:6-7	
71.		LEWANCZUK, Richard Z. et al. (2004) "Comparison of the [13 C] Glucose Breath Test to the Hyperinsulinemic-Euglycemic Clamp When Determining Insulin Resistance" <i>Diabetes Care</i> 27(2):441-447	
72.		LIPKIN, M. (1987) "Proliferation and Differentiation of Normal and Diseased Gastrointestinal Cells" In <i>Physiology of the Gastrointestinal Tract</i> , L.R. Johnson ed., Raven Press, New York, pp. 255-284	
73.		LIPKIN, Martin et al. (1963) "Cell Proliferation Kinetics in the Gastrointestinal Tract of Man. I. Cell Renewal in Colon and Rectum" <i>Journal of Clinical Investigations</i> 42(6):767-776	
74.		MAENTAUSTA, O. et al. (1979) "Radioimmunoassay of Conjugated Cholic Acid, Chenodeoxycholic Acid, and Deoxycholic Acid from Human Serum, with Use of ^{125}I -Labeled Ligands" <i>Clin. Chem.</i> 25(2): 264-268	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/664,513
				Filing Date	September 16, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	5	of	8	Attorney Docket Number 416272003700	

	75.	MARGOLICK, J.B. et al. (1995) "Failure of T-cell Homeostasis Preceding AIDS in HIV-1 Infection," <i>Nature Medicine</i> , 1(7):674-680	
	76.	MCCLOSKEY, J.A. (1990) "Electron Ionization Mass Spectra of Trimethylsilyl Derivatives of Nucleosides," <i>Meth. Enz.</i> 193:825-841	
	77.	MCCUNE, J.M. (1997) "Thymic Function in HIV-1 Disease," <i>Seminars in Immunology</i> 9:397-404	
	78.	MCLEAN, A.R. et al. (1995) "In Vivo Estimates of Division and Death Rates of Human T Lymphocytes," <i>Proc. Natl. Acad. Sci USA</i> 92:3707-3711	
	79.	MEIER, P.R. et al. (March 1981) "Rates of Protein Synthesis and Turnover in Fetal Life," <i>Am J Physiol.</i> , 240(3):E320-E324	
	80.	MELLORS, J.W. et al. (1995) "Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion," <i>Ann. Intern. Med.</i> 122:573-579.	
	81.	MELLORS, J.W. et al. (1996) "Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma," <i>Science</i> , 272:1167-70	
	82.	MESSMER, Bradley T. et al. (Feb. 10, 2005) "In Vivo Measurements Document the Dynamic Cellular Kinetics of Chronic Lymphocytic Leukemia B Cells," <i>J. Clin. Invest.</i> doi:10.1172/JCI200523409	
	83.	MICHIE, C.A. et al. (1992) "Lifespan of Human Lymphocyte Subsets Defined by CD45 Isoforms," <i>Nature</i> 360:264-265	
	84.	MORRIS, Rebecca J. et al. (1997) "Evidence that a Slowly Cyling Subpopulation of Adult Murine Epidermal Cells Retains Carcinogen" <i>Cancer Research</i> 46: 3061-3066	
	85.	MORRIS, Rebecca J. et al. (1997) "Evidence that Cutaneous Carcinogen-initiated Epithelial Cells from Mice are Quiescent Rather than Actively Cyling" <i>Cancer Research</i> 57:3436-3443	
	86.	MOSIER, D.E. (1995) "CD4.sup.+ Cell Turnover," <i>Nature</i> 375:193-194	
	87.	MURALI-KRISHNA, K. et al. (1998) "Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection," <i>Immunity</i> 8:177-187	
	88.	NEESE, R. A. et al. (Nov. 2002) "Measurement in vivo of Proliferation Rates of Slow Turnover Cells by ² H ₂ O Labeling of the Deoxyribose Moiety of DNA," <i>PNAS</i> , 99(24): 15345-15350	
	89.	OYAIKU, N. et al. (1995) "Role of Apoptosis in HIV Disease Pathogenesis," <i>J. of Clinical Immunology</i> 15(5):217-231	
	90.	PALMER, L.D. et al. (1997) "Telomere Length, Telomerase Activity, and Replicative Potential in HIV Infection: Analysis of CD4+ and CD8+ T Cells from HIV-discordant Monozygotic Twins," <i>J. Experimental</i>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO				Complete If Known	
				Application Number	10/664,513
				Filing Date	September 16, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	6	of	8	Attorney Docket Number	416272003700

		<i>Medicine</i> 185(7):1381-1386	
91.		PAPAGEORGOPoulos, C. et al.(1993) "Toward the Measurement of Protein Synthesis by Mass Isotopomer Distribution Analysis (MIDA):Resolution of Isotopomers in a [d. _{sub} .3]-Leucine Enriched Synthetic Oligopeptide Using Electrospray/Quadrupole Mass Spectrometry (ESI/MS)," <i>Abstract, Federation of American Societies for Experimental Biology</i> 1022:A177	
92.		PARK, S. S., et al. (1997) "Measurement of Small Intestinal Cell Turnover with [6,6, 2H ₂] Glucose," <i>Berkeley Scientific, Abstract</i> 1(2):41-43	
93.		PATTON, G.M. et al. (July 1979) "Measurements of Fatty Acid Synthesis by Incorporation of Deuterium from Deuterated Water," <i>Biochemistry</i> , 18(14):3186-3188	
94.		PERELSON, A.S. et al.(1996) "HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time," <i>Science</i> 271:1582-1586	
95.		PERELSON, A.S. et al.(1997) "Decay Characteristics of HIV-1-Infected Compartments During Combination Therapy," <i>Nature</i> 387:188-191	
96.		POZHARISSKI, K.M. et al. (1980) "Study of Kinetics of Epithelial Cell Populations in Normal Tissues of the Rat's Intestines and in Carcinogenesis." <i>Exp. Path.</i> , Bd. 18:387-406	
97.		REICHARD, P. (1978) "From Deoxynucleotides to DNA Synthesis," <i>Federation Proceedings</i> 37(1):9-14	
98.		REICHARD, P. (1988) "Interactions Between Deoxyribonucleotide and DNA Synthesis," <i>Ann. Rev. Biochem.</i> 57:349-374	
99.		ROCHA, B. et al. (1990) "Accumulation of Bromodeoxyuridine-Labelled Cells in Central and Peripheral Lymphoid Organs: Minimal Estimates of Production and Turnover Rates of Mature Lymphocytes" <i>Eur. J. Immunol.</i> 20:1697-1708	
100.		RODA, Aldo et al. (1980) "Results with Six 'Kit' Radioimmunoassays for Primary Bile Acids in Human Serum Intercompared" <i>Clin. Chem.</i> 26(12): 1677-1682	
101.		ROEDERER, M. (July 1995) "T-Dell Dynamics of Immunodeficiency," <i>Nature Medicine</i> 1(7):621-622	
102.		SAWADA, S. et al. (1995) "Comparison of Autoradiography, Liquid Scintillation Counting and Immunoenzymatic Staining of 5-bromo-2'-deoxyuridine for Measurement of Unscheduled DNA Synthesis and Replicative DNA Synthesis in Rat Liver," <i>Mutation Research</i> 344:109-	

Examiner Signature		Date Considered
-----------------------	--	--------------------

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/664,513
				Filing Date	September 16, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	7	of	8	Attorney Docket Number	416272003700

		116	
103.	SCALISE, K. (Feb. 11-17, 1998) "Tracking T-Cells in AIDS Patients: A Safe Reliable Method of Measuring Human Cell Generation Rates," <i>Berkeleyan</i> , p. 3.		
104.	SHIGENAGA, M.K. et al. (1994) "Assays of Oxidative DNA Damage Biomarkers 8-Oxo-2'-deoxyguanosine and 8-Oxoguanine in Nuclear DNA and Biological Fluids by High-Performance Liquid Chromatography with Electrochemical Detection," <i>Methods in Enzymology</i> 234:16-33		
105.	SMITH, et al. (1983) "The Phosphogluconate Oxidative Pathway," in <u>Principles of Biochemistry</u> , 7th edition, McGraw-Hill Book Company, pp. 417-423.		
106.	SPRENT, J. et al. (1995) "CD4+ Cell Turnover," <i>Nature</i> 375:194		
107.	SUNTER, J.P. et al. (1978) "Cell Population Kinetics in the Epithelium of the Colon of the Male Rat." <i>Virchows Archiv. B Cell Path.</i> 26: 275-287		
108.	TINT, G.S. et al. (1974) "Transformation of 5 α -cholest-7-en-3 β -ol to Cholesterol and Cholestanol in Cerebrotendinous Xanthomatosis" <i>Journal of Lipid Research</i> 15: 256-262		
109.	TRABER, P.G. et al. (1991) "Isolation of Intestinal Epithelial Cells for the Study of Differential Gene Expression Along the Crypt-Villus Axis," <i>Am. J. Physiol.</i> 260:G895-G903		
110.	WADKE, M. et al. (July 1973) "Fatty Acid Synthesis by Liver Perfused with Deuterated and Tritiated Water," <i>Biochemistry.</i> , 12(14):2619-2624		
111.	WAIN-HOBSON, S. (1995) "Virological Mayhem," <i>Nature</i> 373:102		
112.	WALDEMAN, F.M. et al. (1991) "A Comparison Between Bromodeoxyuridine and 3 H Thymidine Labeling in Human Breast Tumors," <i>Modern Path.</i> 4(6):718-722		
113.	WEI, X et al. (1995) "Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection," <i>Nature</i> 373:117-122		
114.	WOLFE, R. (1990) "Isotopic Measurement of Glucose and Lactate Kinetics," <i>Ann. Med.</i> 22:163-170		
115.	WOLTERS et al. (1998) "Rapid CD4+ T-Cell Turnover in HIV-1 Infection: a Paradigm Revisited," <i>Immunol. Today</i> 19(1):44-48		
116.	WOLTERS, K.C. et al. (1996) "T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell Turnover," <i>Science</i> 274:1543-1547		
117.	WOOD, H.G. et al. (1963) "Estimation of Pathways of Carbohydrate		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO				<i>Complete if Known</i>	
				Application Number	10/664,513
				Filing Date	September 16, 2003
				First Named Inventor	Marc K. HELLERSTEIN
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	8	of	8	Attorney Docket Number 416272003700	

		Metabolism," <i>Biochemische Zeitschrift</i> 338:809-847	
	118.	ZHANG, Z-Q. et al. (Feb. 1998) "Kinetics of CD4+ T Cell Repopulation of Lymphoid Tissues after Treatment of HIV-1 Infection," <i>Proc. Natl. Acad. Sci. USA</i> 95:1154-1159	
	119.	ZILVERSPLIT, D.B. et al. (1943) "On the Calculation of `Turnover Time` and `Turnover Rate` from Experiments Involving the Use of Labeling Agents," <i>J. of General Physiology</i> 26(3):325-331	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sf-1910128